Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy
Authors:
- 1 April 2017
- journal article
- research article
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 8 (2) , 347-351
Abstract
Background: Combined hepatocellular-cholangiocarcinoma (HCC-CC) has a reported incidence of less than 5% of primary hepatic malignancies. The treatment approach to this malignancy is undefined. Our objective of this case series is to provide some insight into chemotherapy and/or targeted therapy in this setting. Methods: Pathologic and radiographic review confirmed seven combined HCC-CC patients during a 5-year time frame [2009–2014]. Data points were demographics, chemotherapy and/or targeted therapy given in the first and second-line setting, localized treatment if given, first radiographic result, progression-free survival (PFS), and overall survival (OS). Results: Seven patients were identified. Front-line treatment showed a median PFS of 3.4 months. Total median OS was 8.3 months. Regimens given included gemcitabine alone +/− bevacizumab, gemcitabine + platinum (GP) +/− bevacizumab, and sorafenib. Front-line treatment with these regimens showed progressive disease in 71% (5 patients) on first radiographic scan with all patients who received sorafenib front-line progressing at that restaging. Disease-control (complete response + partial response + stable disease) was seen in 29% of patients (2 patients) with 1 patient receiving GP and 1 patient receiving gemcitabine + bevacizumab. Of note, 2 patients that received GP +/− bevacizumab in the second-line setting had disease control on first radiographic scan. Conclusions: Our retrospective review speaks to the rarity of this malignancy and challenges that are associated with its diagnosis and treatment. GP +/− bevacizumab showed disease control in first or second-line treatment in 3 patients. Treatment with this regimen in this rare malignancy subgroup warrants further investigation.Keywords
This publication has 11 references indexed in Scilit:
- Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS databaseHPB, 2016
- Clinicopathological features and prognosis of combined hepatocellular carcinoma and cholangiocarcinoma after surgeryHepatobiliary & Pancreatic Diseases International, 2014
- Characteristics of combined hepatocelluar-cholangiocarcinoma and comparison with intrahepatic cholangiocarcinomaEuropean Journal of Surgical Oncology, 2014
- Current update on combined hepatocellular-cholangiocarcinomaEuropean Journal of Radiology Open, 2014
- Long-Term Outcome of Liver Transplantation for Combined Hepatocellular Carcinoma and CholangiocarcinomaTransplantation Proceedings, 2013
- Management of combined hepatocellular-cholangiocarcinoma: a case report and literature review.2012
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- A Case of Combined Hepatocellular-Cholangiocarcinoma with Favorable Response to Systemic ChemotherapyCancer Research and Treatment, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Combined Hepatocellular and Cholangiocarcinoma: a Clinicopathologic Study of 26 Resected CasesJapanese Journal of Clinical Oncology, 2003